The case for & against
Bull & Bear analysis
Bullish
ALX Oncology, Inc. (NASDAQ: ALXO) operates as a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. Positioned primarily in the oncology sector, its lead products include Avorpacept, an anti-CD47 antibody, and AOX 2004, a novel antibody-drug conjugate targeting EGFR. The company addresses significant unmet needs particularly in HER2-positive cancers and is advancing into other related indications, aiming to enhance patient outcomes and survival rates.
Bull says
- ↑65% ORR in HER2+ CD47-high cohort validates lead asset
- ↑$67 M cash supports trials through Q1 2027 without dilution
- ↑EPS forecasts improved from ($0.66) to ($0.63) reflects analyst optimism
- ↑CD47 biomarker focus drives personalized-medicine partnerships
- ↑Median PFS of 22 months bolsters case for accelerated FDA path
- ↑High book-to-price ratio and dividend yield signal undervaluation
Bear says
- ↓Continued net losses (EPS ~($0.63)) hinder value creation
- ↓Elevated leverage increases refinancing and interest-rate risk
- ↓Mandatory Phase III trial extends timeline and costs
- ↓FDA scrutiny over companion diagnostic may stall approval
- ↓Crowded HER2 space challenges differentiation of Avorpacept
- ↓Small scale versus large biotech rivals amplifies execution risk
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-10-2026bullish
Transcript signals
Bull points
- As we've seen, all of the patients who were centrally assessed as HER2-positive and who overexpressed CD47 in their cancer cells achieved confirmed response to the combination of avorapazep plus anidatinib.
- So these data are really why we're so excited about moving forward with the development of avorpicep in HER2-positive breast cancer.
- We estimate that there are approximately 20,000 addressable patients who are HER2 positive and overexpressed CD47, representing a $2 billion to $4 billion market opportunity in the United States, the five major European markets, and Japan.
Bear points
- I would think that PFS might be too immature to report, but it really depends on the continued progress.
- we do not have an expectation that we could replicate a hundred percent response rate, which are very difficult to achieve, particularly with regulatory approvals for single-arm trials that involve a combination of two agents.
Read full transcript analysis ›